<DOC>
	<DOCNO>NCT00279188</DOCNO>
	<brief_summary>The long-term course asthma show variable outcome regard incidence exacerbation decline lung function time . The present study aim : 1. investigate whether asthma management additionally guide degree bronchial hyperresponsiveness lead good outcome 2. examine predictor among clinical inflammatory disease marker long-term decline lung function</brief_summary>
	<brief_title>Asthma Management Project University Leiden</brief_title>
	<detailed_description>Asthma associate specific inflamma¬tory state airway . Assuming degree airway inflammation determinant long-term disease outcome , follow , asthma therapy aim maximal reduction airway inflammation , addition reduce symptom . However , accord current guideline , therapy direct clinical severity disease . There increase evidence bronchial hyper¬respon¬siveness use non-invasive reflection airway inflamma¬tion [ 29 ] . However , still unknown whether bronchial responsiveness provide relevant additional information adjust therapy follow-up patient asthma . Therefore , study : 1. compare disease outcome two parallel group patient asthma , receive therapy aim either clinical severity , therapy aim clinical severity , bronchial hyper¬responsiveness methacho¬li¬ne . The outcome assess three level . First , severity , second , lung function bronchial responsive¬ness , third , humoral , cellular , histological index airway inflamma¬tion . To end ass symptom , lung function , bronchial respon¬siveness , immunological parameter blood , every three month . Furthermore , bronchos¬copy bronchoalveolar lavage bronchial biopsy carry provide material immunologic pathologic anatomical examination , begin end study . 2. analyse predictor among clinical- inflammatory parameter exacerbation long-term decline lung function long-term follow-up</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Asthma base GINA guideline ( www.ginasthma.org ) oral steroid</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>Bronchial hyperresponsiveness</keyword>
	<keyword>Atopy</keyword>
	<keyword>Inhaled steroid</keyword>
	<keyword>Exacerbations</keyword>
	<keyword>Lung function decline</keyword>
	<keyword>Prognosis</keyword>
</DOC>